A Phase I Multicenter, Open Label Study of Enadenotucirev Combined With PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enadenotucirev (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions
Acronyms SPICE
Sponsors Akamis Bio; PsiOxus Therapeutics

05 Jan 2023 According to an Akamis Bio media release, PsiOxus Therapeutics has changed its name to Akamis Bio.
07 Jun 2022 Results of pooled analysis from three Phase 1 dose-escalation studies in advanced/metastatic epithelial cancer (NCT02636036), FORTITUDE (NCT03852511) and STAR ( NCT04053283), presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
02 Nov 2021 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com